Most undervalued stock, page-233

One thing to remember about these trials, is they are targeted at being a therapeutic. Not an actual preventive vaccine.

This is the shortest path to market.

The effectiveness of it as a vaccine is another (more vast and expensive study) all together, Conclusions of this trial on infected people do not preclude it from being an effective vaccine.

To reach market as a therapeutic, it only needs to be proven as good or better than existing treatments for sufferers.

That in itself is a viable market, even if it isn't a cure.

While it may not prevent the spread of hsv2 from an afflicted person. The reduction of the symptoms sufferers experience is something that sufferers seem to be chasing with current available treatments they take.


I would be happy if we could capture a share of this market.